文献速递心脑血管急症

PCI术后高危患者替格瑞洛单药与联合阿司匹林比较

Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
PubMed 文献 · N Engl J Med · 2019-09-26
一句话结论PCI术后高危患者完成3个月双联抗血小板治疗后,替格瑞洛单药较加用阿司匹林降低临床相关出血,且死亡、心梗或卒中风险不增高。

TWILIGHT双盲试验纳入9006例PCI术后高危患者,先接受3个月替格瑞洛加阿司匹林治疗,无大出血或缺血事件者7119例随机继续替格瑞洛加安慰剂或加阿司匹林1年。主要终点BARC 2、3或5型出血在替格瑞洛加安慰剂组为4.0%,替格瑞洛加阿司匹林组为7.1%(HR 0.56;95%CI 0.45-0.68;P<0.001)。BARC 3或5型出血分别为1.0%和2.0%(HR 0.49;95%CI 0.33-0.74)。死亡、非致死性心梗或非致死性卒中两组均为3.9%(差异-0.06个百分点;95%CI -0.97至0.84;HR 0.99;95%CI 0.78-1.25;非劣效P<0.001)。

要点

  • PCI术后高危患者完成3个月替格瑞洛加阿司匹林且无大出血或缺血事件后,随机继续替格瑞洛加安慰剂1年,BARC 2、3或5型出血发生率为4.0%,低于替格瑞洛加阿司匹林组的7.1%(HR 0.56;95%CI 0.45-0.68;P<0.001)。
  • BARC 3或5型出血在替格瑞洛加安慰剂组为1.0%,替格瑞洛加阿司匹林组为2.0%(HR 0.49;95%CI 0.33-0.74)。
  • 死亡、非致死性心梗或非致死性卒中在替格瑞洛加安慰剂组和替格瑞洛加阿司匹林组均为3.9%(差异-0.06个百分点;95%CI -0.97至0.84;HR 0.99;95%CI 0.78-1.25;非劣效P<0.001)。
  • 该策略适用于PCI术后高危且已完成3个月双联抗血小板治疗、未发生大出血或缺血事件的患者。

适用人群与场景

  • 接受经皮冠状动脉介入治疗(PCI)且出血或缺血事件高危的患者。
  • 已完成3个月替格瑞洛加阿司匹林治疗,且未发生大出血事件或缺血事件的患者。

处置流程与药物剂量

  • PCI术后高危患者先接受替格瑞洛加阿司匹林治疗3个月。
  • 3个月后未发生大出血事件或缺血事件者,继续替格瑞洛并随机加用安慰剂或阿司匹林治疗1年。

研究设计与关键结果

  • TWILIGHT为双盲试验,纳入9006例患者,其中7119例在3个月后接受随机化。
  • 随机化至1年期间,主要终点BARC 2、3或5型出血在替格瑞洛加安慰剂组发生率为4.0%,替格瑞洛加阿司匹林组为7.1%(HR 0.56;95%CI 0.45-0.68;P<0.001)。
  • BARC 3或5型出血在替格瑞洛加安慰剂组为1.0%,替格瑞洛加阿司匹林组为2.0%(HR 0.49;95%CI 0.33-0.74)。
  • 死亡、非致死性心梗或非致死性卒中在替格瑞洛加安慰剂组和替格瑞洛加阿司匹林组均为3.9%(差异-0.06个百分点;95%CI -0.97至0.84;HR 0.99;95%CI 0.78-1.25;非劣效P<0.001)。

证据类型、等级与局限

  • 证据类型:双盲随机对照试验(TWILIGHT,NCT02270242),由AstraZeneca资助。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 对于PCI术后高危且已完成3个月替格瑞洛加阿司匹林、无大出血或缺血事件的患者,替格瑞洛单药较替格瑞洛加阿司匹林降低临床相关出血,且死亡、心梗或卒中风险不增高。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary intervention (PCI).

METHODS: In a double-blind trial, we examined the effect of ticagrelor alone as compared with ticagrelor plus aspirin with regard to clinically relevant bleeding among patients who were at high risk for bleeding or an ischemic event and had undergone PCI. After 3 months of treatment with ticagrelor plus aspirin, patients who had not had a major bleeding event or ischemic event continued to take ticagrelor and were randomly assigned to receive aspirin or placebo for 1 year. The primary end point was Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding. We also evaluated the composite end point of death from any cause, nonfatal myocardial infarction, or nonfatal stroke, using a noninferiority hypothesis with an absolute margin of 1.6 percentage points.

RESULTS: We enrolled 9006 patients, and 7119 underwent randomization after 3 months. Between randomization and 1 year, the incidence of the primary end point was 4.0% among patients randomly assigned to receive ticagrelor plus placebo and 7.1% among patients assigned to receive ticagrelor plus aspirin (hazard ratio, 0.56; 95% confidence interval [CI], 0.45 to 0.68; P<0.001). The difference in risk between the groups was similar for BARC type 3 or 5 bleeding (incidence, 1.0% among patients receiving ticagrelor plus placebo and 2.0% among patients receiving ticagrelor plus aspirin; hazard ratio, 0.49; 95% CI, 0.33 to 0.74). The incidence of death from any cause, nonfatal myocardial infarction, or nonfatal stroke was 3.9% in both groups (difference, -0.06 percentage points; 95% CI, -0.97 to 0.84; hazard ratio, 0.99; 95% CI, 0.78 to 1.25; P<0.001 for noninferiority).

CONCLUSIONS: Among high-risk patients who underwent PCI and completed 3 months of dual antiplatelet therapy, ticagrelor monotherapy was associated with a lower incidence of clinically relevant bleeding than ticagrelor plus aspirin, with no higher risk of death, myocardial infarction, or stroke. (Funded by AstraZeneca; TWILIGHT ClinicalTrials.gov number, NCT02270242.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019. PMID: 31556978. doi:10.1056/NEJMoa1908419

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。